Treatment of Metastatic Breast Cancer with Capecitabine: Efficacy and Toxicity; [Metastatik Meme Kanserinin Tedavisinde Capecitabine: Etkinlik ve Toksisite]

Simple item page
dc.contributor.authorSezgin V.C.
dc.contributor.authorŞanli U.A.
dc.contributor.authorKarabulut B.
dc.contributor.authorUslu R.
dc.contributor.authorMüezzinoǧlu G.G.
dc.contributor.authorGöker E.
dc.contributor.authorÖzdemir N.
dc.date.accessioned2024-07-22T08:24:48Z
dc.date.available2024-07-22T08:24:48Z
dc.date.issued2003
dc.description.abstractCapecitabine is an oral fluoropyrimidine that mimics continuous infusion 5-fluorouracil. As an oral agent, capecitabine is more convenient for patients and medical oncologists, and avoids the complications associated with venous access. Clinical trials have demonstrated the efficacy and tolerability of capecitabine in anthracycline and taxane pretreated metastatic breast cancer. In this study, we evaluated efficacy and tolerability of capecitabine in anthracycline and taxane pretreated metastatic breast cancer retrospectively. A total of 42 patients received oral capecitabine 2000 mg/m2/daily, on days 1-14 of each 3-week treatment cycle. Complete response not achieved. The partial and stable response rate were %19, %45,2 respectively. Median progression free survival time was 5 months. Additionally, cerbB2 subgroup analysis was performed. Progression free survival was longer in cerbB2 negative group than cerbB2 positive group. Difference between two groups was statistically significant. Oral capecitabine monotherapy demonstrated an acceptable safety profile. There was a low incidence of grade 3-4 adverse event. Capecitabine therapy, has antitumor activity and an acceptable safety profile in this setting.
dc.identifier.issn13018825
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20134
dc.language.isoTurkish
dc.subjectcapecitabine
dc.subjectfluoropyrimidine derivative
dc.subjectfluorouracil
dc.subjecttaxane derivative
dc.subjectadult
dc.subjectadverse drug reaction
dc.subjectaged
dc.subjectarticle
dc.subjectbreast carcinoma
dc.subjectcancer survival
dc.subjectclinical article
dc.subjectdrug effect
dc.subjectdrug efficacy
dc.subjectdrug response
dc.subjectdrug safety
dc.subjectdrug tolerability
dc.subjecthuman
dc.subjectmetastasis
dc.subjectmonotherapy
dc.subjectretrospective study
dc.subjectsurvival time
dc.subjectTurkey (republic)
dc.titleTreatment of Metastatic Breast Cancer with Capecitabine: Efficacy and Toxicity; [Metastatik Meme Kanserinin Tedavisinde Capecitabine: Etkinlik ve Toksisite]
dc.typeArticle

Files

Collections

Scopus Koleksiyonu